Welcome to our dedicated page for Morgan Stanley SEC filings (Ticker: MS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Morgan Stanley’s disclosures are a treasure trove of information on everything from trading Value-at-Risk to the health of its $4T wealth-management franchise. But finding those details inside a 300-page report is tedious. This page curates every filing the firm submits to EDGAR, then layers Stock Titan’s AI so Morgan Stanley SEC filings are explained simply.
Need the latest Morgan Stanley quarterly earnings report 10-Q filing or an Morgan Stanley 8-K material events explained summary? We post them in real time and generate concise AI-powered breakdowns of segment revenue, capital ratios, and liquidity buffers. Curious about management’s trading activity? Our alerts track Morgan Stanley insider trading Form 4 transactions and show Morgan Stanley Form 4 insider transactions real-time, highlighting patterns before they hit the news. When proxy season arrives, the platform pinpoints pay packages inside the Morgan Stanley proxy statement executive compensation section—no more hunting through exhibits.
Professionals use these tools to:
- Compare quarter-over-quarter margins with a click using our Morgan Stanley earnings report filing analysis
- Monitor Morgan Stanley executive stock transactions Form 4 for buy-sell trends
- Read a Morgan Stanley annual report 10-K simplified summary that clarifies risk factors, legal reserves, and capital plans
- Ask natural questions like “understanding Morgan Stanley SEC documents with AI” and receive instant answers
Whether you’re gauging deal pipelines, stress-testing balance sheets, or assessing leadership’s confidence, our AI-powered summaries, expert context, and real-time updates turn raw filings into actionable knowledge—faster than opening a PDF.
Regulus Therapeutics Inc. ("Regulus") has filed a Post-Effective Amendment No. 1 to 20 previously effective Form S-8 registration statements. The amendment formally terminates the registration of all remaining, unsold shares of Regulus common stock that had been set aside for issuance under a variety of equity incentive, inducement and employee stock-purchase plans dating from 2009 through 2025. The affected plans include the 2009 and 2012 Equity Incentive Plans, multiple Employee Stock Purchase Plans (2012 & 2022), the 2019 Equity Incentive Plan and the 2021 Inducement Plan, among others.
The filing follows the consummation of Regulus’ merger with Novartis AG on 25 June 2025, executed under the 29 April 2025 Agreement and Plan of Merger. Redwood Merger Sub Inc., a wholly-owned Novartis subsidiary, was merged into Regulus, with Regulus surviving as a wholly-owned subsidiary of Novartis. Consequently, Regulus has ceased all public offerings of its securities, making the S-8 registrations unnecessary.
Key implications for investors:
- Any options or rights that remained unexercised under the listed equity plans will no longer be eligible for issuance of new Regulus common shares under the Securities Act.
- The deregistration is an administrative step that typically follows completion of an acquisition; it does not disclose merger consideration, exchange ratios, or post-merger integration plans.
- The filing confirms that Regulus is no longer an independent, Exchange-Act reporting company; future disclosures will occur through Novartis, if material.
No financial statements, earnings data, or forward-looking statements are included in the document.
Morgan Stanley Finance has announced Worst-of SPX, NDX and RTY Trigger PLUS securities due August 5, 2030. These structured notes offer leveraged exposure to the worst-performing index among the S&P 500, Nasdaq-100, and Russell 2000 indices.
Key features include:
- Maximum payment at maturity: 176% to 181% of principal ($1,760 to $1,810 per security)
- Leverage factor: 400%
- Downside threshold: 70% of initial level
- Estimated value: $944.10 per security
Notable risks include no principal protection, limited appreciation potential, and exposure to the worst-performing index. The securities don't pay interest and are subject to Morgan Stanley's credit risk. The payment at maturity will be determined solely by the worst-performing underlier's value on July 31, 2030. If any underlier declines more than 30% from its initial level, investors will be fully exposed to the downside of the worst performer.
Morgan Stanley Finance has announced SX5E Market-Linked Notes due August 5, 2030, offering investors exposure to the EURO STOXX 50® Index with enhanced upside potential. Key features include:
- A 130% to 135% participation rate in the index's positive performance
- Principal protection against negative index performance
- Estimated value of $952.00 per note
- 5-year maturity with observation date on July 31, 2030
The notes' payment structure offers asymmetric returns: investors receive 130-135% of any positive index performance while being protected against losses, maintaining the $1,000 principal even if the index declines. Notable risks include credit risk of Morgan Stanley, no interim interest payments, and limited secondary market liquidity. The notes are guaranteed by Morgan Stanley and will trade under CUSIP 61778NAV3.
Morgan Stanley Finance LLC has announced Market-Linked Notes due August 5, 2030, based on the performance of the EURO STOXX 50 Index. The notes, fully guaranteed by Morgan Stanley, are being offered at $1,000 per note with an estimated value of approximately $952.00.
Key features include:
- No interest payments over the term
- Principal protection at maturity regardless of index performance
- Participation rate of 130% to 135% in index gains
- If final index level exceeds initial level, investors receive principal plus enhanced upside participation
- If final index level is equal to or below initial level, investors receive only principal
Notable risks include credit risk of Morgan Stanley, no interest payments, and value determined solely by index performance on the observation date (July 31, 2030). The notes will not be listed on any securities exchange and involve costs that reduce their economic terms compared to direct index investment.
Morgan Stanley Finance LLC, guaranteed by Morgan Stanley, plans to issue market-linked notes tied to the EURO STOXX 50 Index (SX5E). The notes offer 114%-119% upside participation on any positive index performance observed on July 31 2029, with full principal repayment at maturity even if the index declines. Key terms include a $1,000 face value, pricing on July 31 2025, and maturity on August 3 2029 (4-year term). The preliminary estimated value is $958.80 (≈95.9% of face), reflecting issuance and hedging costs.
Key structural features
- No periodic coupons; all return realized at maturity.
- Amount payable depends solely on index level at the single observation date; interim movements are irrelevant.
- Notes will not be listed, and secondary liquidity may be limited.
- Credit exposure to Morgan Stanley; MS Finance LLC is a wholly owned funding vehicle without independent assets.
Principal risk highlights
- Investors may earn only principal if SX5E is flat or negative.
- The 4.1% issue-price premium versus estimated value creates negative yield if held to maturity without index appreciation.
- Market value can be volatile, influenced by MS credit spreads and trading in related instruments.
- Investors may incur taxable income annually under U.S. OID rules.
Overall, the product suits investors seeking European equity exposure with principal protection and are comfortable with MS credit risk and the lack of interim income.
Morgan Stanley Finance has announced Market-Linked Notes due August 5, 2030, tied to the S&P 500® Futures Excess Return Index (SPXFP). Key features include:
- Participation rate of 128% to 133% in the index's positive performance
- Principal protection against negative index performance
- Estimated value of $954.30 per note
- 5-year maturity (2025-2030)
The notes offer enhanced upside potential while maintaining principal protection, with payments at maturity ranging from $1,000 (minimum) to potentially higher returns based on index performance. For example, a 40% index increase would yield a 51.2% return (at 128% participation rate).
Key risks include credit risk of Morgan Stanley, no interest payments, limited secondary market trading, and potential tax implications prior to maturity. The notes' value may be affected by market factors, and the final payment depends solely on the index's performance at maturity.
Morgan Stanley Finance LLC announces Worst-of SPX and SX5E Dual Directional Buffered PLUS securities due August 5, 2030. Key features include:
- Underliers: S&P 500® Index (SPX) and EURO STOXX 50® Index (SX5E)
- Leverage factor: 212% to 227%
- Buffer amount: 20% with 80% maximum loss
- Absolute return participation rate: 50%
- Estimated value: $953.00 per security (±$55.00)
The payment at maturity will be based on the worst-performing underlier's performance. Notable risks include: no interest payments, exposure to both indices' price risks, credit risk of Morgan Stanley, and limited secondary market trading. The security offers leveraged upside potential with some downside protection through the buffer, making it suitable for investors seeking enhanced returns while accepting some market risk.
Morgan Stanley Finance has announced URA Buffered Jump Securities due August 13, 2026, linked to the Global X Uranium ETF (URA). Key features include:
- Fixed upside payment of $132.50 per security (13.25% return) if the underlier is flat or up at maturity
- 25% downside buffer protecting against first 25% of losses
- Maximum loss capped at 75% of principal
- Estimated value of $965.30 per security
The securities offer conditional downside protection while maintaining upside potential in the uranium sector. Notable risks include: credit risk of Morgan Stanley, limited appreciation potential, no interim payments, and market price influenced by unpredictable factors. The product particularly targets investors seeking exposure to the uranium sector with partial downside protection.
Morgan Stanley Finance LLC has announced SPX Market-Linked Notes due January 16, 2030, offering investors exposure to S&P 500® Index performance with principal protection. Key features include:
- 100% participation rate in index gains up to a maximum payment of $1,400 per note (140% of principal)
- Principal protection against market downside - minimum payment of $1,000 per note regardless of index performance
- Notes are priced at $973.90 estimated value per note
- 4.5-year term from July 11, 2025 pricing date to January 16, 2030 maturity
Key risks include: no interest payments, limited upside potential due to payment cap, credit risk of Morgan Stanley, limited secondary market liquidity, and potential required tax recognition before maturity. The notes' value will be determined solely by the S&P 500® Index level on the January 11, 2030 observation date.
Morgan Stanley Finance has announced SPX Buffered PLUS Notes due January 16, 2030, offering investors exposure to the S&P 500 Index with enhanced features. Key terms include:
- Maximum Return: 54% (capped at $1,540 per $1,000 principal)
- Leverage Factor: 150% participation in index gains
- Downside Protection: 10% buffer against losses
- Estimated Value: $969.10 per security
The structured note offers enhanced upside potential up to the cap while providing partial protection against market declines. Investors maintain full principal if the S&P 500 declines by 10% or less, with one-for-one losses beyond the buffer. Key risks include credit risk of Morgan Stanley, limited secondary market liquidity, and capped upside potential. The notes do not provide dividend payments or direct index exposure.